Abbott's Libre® Technology is the first continuous glucose monitor associated with reduced hospitalizations for cardiac complications in diabetic patients

New data reveal a 78% reduction in cardiovascular disease-related hospitalizations in patients with type 1 diabetes who have past severe hypoglycemic episodes.

Abbott Parkdisease., May 15, 2025 /PRNewswire/ -Abbott (NYSE: ABT) today published the results of a reflex real-world study showing that the use of Freestyle Libre® continuous glucose monitoring (CGM) technology is associated with a significant reduction in the risk of cardiac complications in diabetic patients. For the first time, the data show that CGM technology can help reduce the severity of cardiovascular complications in individuals with type 1 diabetes regardless of their previous history of hypoglycemic events and heart disease-related hospitalizations.

Diabetes remains a serious chronic disease worldwide, affecting approximately 589 million people3 and is often accompanied by cardiovascular complications. People with type 4 type 1 and type 2 diabetes can develop 2-4 times more heart disease than people without diabetes. Adults with type 1 diabetes, with severe hypoglycemic episodes, are twice as likely to be hospitalized due to heart-related issues.

For people with diabetes, the reflective results suggest that the use of Libre technology may also lead to reduced healthcare costs due to reduced hospitalizations associated with cardiac complications.

“These results are surprising because of the dual benefits of CGM technology in managing diabetes and associated cardiovascular complications,” said one of the study's leading authors. David NathansonMD, PhD, Karolinska University Hospital in Sweden. “CGM enables people to actively manage diabetes and choose their informed health through constant real-time feedback on glucose levels. This data shows that using CGM is linked to significantly reduced hospitalizations associated with heart problems.

The findings also reveal that using Libre Biowearable technology compared to those who used traditional blood glucose monitors, the risk of cardiovascular hospitalization was reduced by 80% among people with type 1 diabetes who had no prior history of cardiovascular disease. For individuals with a history of cardiovascular disease, the risk of hospitalization was reduced by 49%.

“These data are transformative and show how valuable freestyle Libre Technology is to manage both diabetes and heart health and help millions of people live healthy lives,” he said. Mahmoud KazemiMD, Chief Medical Officer of the Diabetes Care Business at Abbott. “The benefits of the mind make Libre easier for people to control their health.”

Reflex studies considered cardiovascular disease-related scopes, including non-fatty heart attacks, non-fatty strokes, coronary artery disease, heart failure, atrial fibrillation, and cardiovascular death.

“I regularly treat people with diabetes who have vascular problems, resulting in heart attacks, strokes and amputations.” Ramji AjanMD, Professor of Metabolic Medicine at the University of Leeds and NHS Trust, Leeds Teaching Hospital. “These vascular issues, which are put together as cardiovascular disease, continue to be the main cause of health and death in diabetic patients, and we are very excited to see data showing a significant reduction in cardiovascular disease-related hospitalizations.

About Research About Research:
The reflex research funded by Abbott was a real-world retrospective study conducted using data from the Swedish National Diabetes Register (NDR). Sweden.8

Research published during that time October 2024 and April 2025assessment: 1) Effects of intermittently scanned CGM vs. glucose monitoring on HBA1C levels and hospitalization in adults with insulin-treated type 2 diabetes. 2) The effects of intermittently scanned CGM and glucose monitoring on metabolism and vascular complications and hospitalization rates of HBA1C levels in adults with type 1 diabetes; 9 3) The risk of risk of post-spore sclerosis after sporosclerosis in interspiragodonemia in type 1 diabetes patients is 9 3) CGM users and glucose monitoring users.

About Freestyle Ribble:
Abbott continues his groundbreaking pioneering skills to help people living with diabetes. The company revolutionized diabetes care 10 years ago with its world-leading freestyle Libre continuous glucose monitoring portfolio. Today, it is used by over 7 million people in over 60 countries. Over 40 countries have full or partial rebates for the Ribble System.

About Abbott:
Abbott is a global healthcare leader who helps people live more fully at every stage of their life. Our life-changing technology portfolio spans the spectrum of healthcare with major businesses and products of diagnostics, medical devices, nutrition, and branded generic drugs. Our 114,000 colleagues serve people in over 160 countries.

Connect with us on Abbott.com and LinkedIn, Facebook, Instagram, X and YouTube.

Formulation only. For important safety information, please visit freestylelibre.us.

Source Abbott